Strychnine-like multifocal myoclonus and seizures in extremely high- dose opioid administration: Treatment strategies

Journal of Pain and Symptom Management

Volumn 14, Issue 1, 1997, Pages 51-58

  Hagen, Neil ^a,b   Swanson, Rick ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

Author keywords

Cancer pain; Myoclonus; Opioid; Seizures; Toxicity

Indexed keywords

MIDAZOLAM; OPIATE; STRYCHNINE;

ADULT; AGED; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; HUMAN; MALE; MYOCLONUS; SEIZURE; STIMULUS RESPONSE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; ANESTHETICS, INTRAVENOUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDAZOLAM; MYOCLONUS; SEIZURES; STRYCHNINE;

EID: 0030802901     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(97)00001-8     Document Type: Article

References (27)

1. Tempelhoff R, Modica P, Bernardo K, Edwards I. Fentanyl-induced electrocardiographic seizures inpatients with complex partial epilepsy. J Neurosurg 1992;77:201-208.
2. Sprung J, Shedewie HK. Apparent focal motor seizure with Jacksonian march induced by fentanyl: case report and review of the literature. J Clin Anesth 1992;4:139-143.
3. Challoner KR, McCarron MM, Newton EJ. Pentazocine (Talwin) intoxication: report of 57 cases. J Emerg Med 1990;8:67-74.
4. Szeto H, Inturrrisi C, Honde R, Saal S, Cheigh J, Reidenberg M. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1977;86: 738-741.
5. Kaiko R, Foley K, Grabinski P, et al. Central nervious systems excitatory effects of meperidine in cancer patients. Ann Neurol 1983;13:180-185.
6. Miller R, Jick H. Clinical effects of meperidine in hospitalized cancer patients. J Clin Pharmacol 1978;18:180-189.
7. Eisele J, Grigsby E, Dea G. Clonazepam treatment of myoclonic contractions associated with high-dose opioids: case report. Pain 1992;49:231-232.
8. Babul N, Darke AC. Putative role of hydromorphone metabolites in myoclonus. Pain 1993;52:260-261.
9. MacDonald N, Der L, Allan S, Champion P. Opioid hyperexcitability: the application of alternative opioid therapy. Pain 1993;53:353-355.
10. Portenoy RK, Thaler HT, Inturissi CE, Friedlander-Klar H, Foley KM. The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion inpatients with pain and normal renal function. Clin Pharmacol Ther 1992;51:422-431.
11. Cowan A, Geller E, Adler M. Classification of opioids on the basis of change in seizure threshold in rats. Science 1979;206:465-467.
12. Glare PA, Walsh TD, Pippenger CE. Normorphine, a neurotoxic metabolite? Lancet 1990;335: 725-726.
13. Osborne R, Thompson, P, Joel S, Trew D, Patel N, Slevin M. The analgesic activity of morphine-6-glucuronide. Br J Pharmacol 1992;34:130-138.
14. Hagen NA, Portenoy R, Inturrisi C. Chronic nausea associated with morphine-6-glucuronide. J Pain Symptom Manage 1991;6:125-128.
15. Fainsinger R, Schoeller T, Botskin M, Bruera E. Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993;9:53-55.
16. Babul N, Darke AC, Hagen NA. Hydromorphone-3-glucuronide pharmacokinetics in renal failure [peer-reviewed letter]. J Pain Symptom Manage 1995;10:184-186.
17. Potter JM, Reid DB, Shaw RJ, Hackett P, Hickman PI. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ 1989;299:150-153.
18. Gilbert PE, Martin WR. Antagonism of the convulsant effects of heroin, α-propoxyphene, meperidine, normeperidine and thebaine by naloxone in mice. J Pharmacol Exp Ther 1975;192:538-541.
19. Werz MA, MacDonald RL. Opiate alkaloids antagonize postsynoptic glycine and GABA responses: correlation with convulsant action. Brain Res 1982;236:107-119.
20. Klaassen CD. Nonmetalic environmental toxicants: air pollutants, solvents and vapors, and pesticides. In: Goodman AG, Rail TW, Nies AS, Taylor P, eds. The pharmacological basis of therapeutics, 8th ed. New York: Pergamon, 1990:1632-1633.
21. Bohn HP, Reich L, Suljaga-Petchel K. Inadvertent intrathecal use of ionic contrast media for myelography. Am J Neuroradiol 1992;12:1515-1519.
22. DeConno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991;47:337-339.
23. Yaksh TL, Hardy GJ, Onofrio BM. High doses of spinal morphine produce non-opiate receptor-mediated hyperesthesia: clinical and theoretic implications. Anesthesiology 1986;64:590-597.
24. Yaksh TL. Behavioral and autonomie correlates of the tactile evoked allodynia produced by spinal glycine inhibition: effects of modulatory receptor systems and excitatory amino acid antagonists. Pain 1989;37:111-123.
25. Watkins LR, Frenk H, Miller J, Mayer DJ. Effect of spinal cord lesions on convulsive activity induced by intrathecal morphine. Brain Res 1984;310:337-345.
26. Inturrisi CE, Hanks G. Opioid analgesic therapy. In: Doyle D, Hanks GWC, MacDonald N, eds. Oxford textbook of palliative medicine. New York: Oxford University Press, 1993:166-182.
27. Yanez A, Sabbe MB, Stevens CW, Yaksh TL. Interaction of midazolam and morphine in the spinal cord of the rat. Neuropharmacology 1990;29:359-364.